Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cogent Biosciences (COGT) Common Equity: 2017-2020

Historic Common Equity for Cogent Biosciences (COGT) over the last 4 years, with Dec 2020 value amounting to $234.7 million.

  • Cogent Biosciences' Common Equity rose 989.50% to $197.2 million in Q3 2021 from the same period last year, while for Sep 2021 it was $197.2 million, marking a year-over-year increase of 989.50%. This contributed to the annual value of $234.7 million for FY2020, which is 638.83% up from last year.
  • As of FY2020, Cogent Biosciences' Common Equity stood at $234.7 million, which was up 638.83% from $31.8 million recorded in FY2019.
  • In the past 5 years, Cogent Biosciences' Common Equity registered a high of $234.7 million during FY2020, and its lowest value of -$48.8 million during FY2017.
  • Its 3-year average for Common Equity is $108.9 million, with a median of $60.2 million in 2018.
  • As far as peak fluctuations go, Cogent Biosciences' Common Equity tumbled by 47.27% in 2019, and later spiked by 638.83% in 2020.
  • Cogent Biosciences' Common Equity (Yearly) stood at -$48.8 million in 2017, then surged by 223.31% to $60.2 million in 2018, then slumped by 47.27% to $31.8 million in 2019, then surged by 638.83% to $234.7 million in 2020.